SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 50.73-2.8%3:19 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (9069)9/9/2003 9:59:36 AM
From: michael_f_murphy  Read Replies (1) of 52153
 
Merck And Alnylam

Tuesday September 9, 8:19 am ET

WHITEHOUSE STATION, N.J. -(Dow Jones)- Merck & Co. and Alnylam Holding Co., a therapeutic RNA interference company, signed a multi-year collaboration agreement to develop RNAi-based technology and therapeutics.
In a press release Tuesday, pharmaceutical company Merck said the companies will work to advance RNAi technology, which uses a natural biological mechanism to inhibit the expression of disease-causing genes and viruses, and jointly apply the technology to develop RNAi-based therapeutics that selectively target human diseases.

Merck will provide Alnylam with a series of drug targets that have well- validated roles in disease and are candidates for a new therapeutic approach using RNAi. Alnylam will develop RNAi compounds against these targets and advance RNAi-based drug candidates through preclinical development. The companies will then decide whether Alnylam, Merck or the two companies together will proceed with the further development and commercialization of each RNAi- based drug candidate.

Under the agreement, Merck will make upfront and annual cash payments and also make an equity investment in Alnylam. The achievement of a pre-specified technology milestone will trigger an additional cash payment and equity investment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext